Gilbert PB - Search Results

1

HIV Vaccine Trials Network: activities and achievements of the first decade and beyond.

Kublin JG, Morgan CA, Day TA, Gilbert PB, Self SG, McElrath MJ, Corey L. Kublin JG, et al. Among authors: gilbert pb. Clin Investig (Lond). 2012 Mar;2(3):245-254. doi: 10.4155/cli.12.8. Clin Investig (Lond). 2012. PMID: 23243491 Free PMC article.

2

Statistical methods for assessing differential vaccine protection against human immunodeficiency virus types.

Gilbert PB, Self SG, Ashby MA. Gilbert PB, et al. Biometrics. 1998 Sep;54(3):799-814. Biometrics. 1998. PMID: 9750238

3

Sieve analysis: methods for assessing from vaccine trial data how vaccine efficacy varies with genotypic and phenotypic pathogen variation.

Gilbert P, Self S, Rao M, Naficy A, Clemens J. Gilbert P, et al. J Clin Epidemiol. 2001 Jan;54(1):68-85. doi: 10.1016/s0895-4356(00)00258-4. J Clin Epidemiol. 2001. PMID: 11165470 Review.

4

What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials.

Gilbert PB, DeGruttola VG, Hudgens MG, Self SG, Hammer SM, Corey L. Gilbert PB, et al. J Infect Dis. 2003 Jul 15;188(2):179-93. doi: 10.1086/376449. Epub 2003 Jul 1. J Infect Dis. 2003. PMID: 12854072

5

Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160.

Lee D, Graham BS, Chiu YL, Gilbert PB, McElrath MJ, Belshe RB, Buchbinder SP, Sheppard HW, Koblin BA, Mayer KH, Keefer MC, Mulligan MJ, Celum CL. Lee D, et al. Among authors: gilbert pb. J Infect Dis. 2004 Sep 1;190(5):903-7. doi: 10.1086/423284. Epub 2004 Jul 29. J Infect Dis. 2004. PMID: 15295694 Clinical Trial.

6

Statistical evaluation of HIV vaccines in early clinical trials.

Moodie Z, Rossini AJ, Hudgens MG, Gilbert PB, Self SG, Russell ND. Moodie Z, et al. Among authors: gilbert pb. Contemp Clin Trials. 2006 Apr;27(2):147-60. doi: 10.1016/j.cct.2005.11.008. Epub 2006 Jan 19. Contemp Clin Trials. 2006. PMID: 16426900

7

Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation.

Li F, Malhotra U, Gilbert PB, Hawkins NR, Duerr AC, McElrath JM, Corey L, Self SG. Li F, et al. Among authors: gilbert pb. Vaccine. 2006 Nov 17;24(47-48):6893-904. doi: 10.1016/j.vaccine.2006.06.009. Epub 2006 Jun 27. Vaccine. 2006. PMID: 16890329

8

Joint inferences on vaccine efficacy against infection and disease with application to the first HIV vaccine efficacy trial.

Cai T, Gilbert PB, Self SG. Cai T, et al. Among authors: gilbert pb. J Biopharm Stat. 2006;16(4):517-38. doi: 10.1080/10543400600719483. J Biopharm Stat. 2006. PMID: 16892911 Clinical Trial.

9

Identification of cross-neutralization determinants by GAP analysis: a mutational behavior approach.

Li F, Gilbert PB, Self SG. Li F, et al. Among authors: gilbert pb. Curr HIV Res. 2007 Jan;5(1):87-96. doi: 10.2174/157016207779316305. Curr HIV Res. 2007. PMID: 17266560

10

HIV-1 CTL-based vaccine immunogen selection: antigen diversity and cellular response features.

Li F, Horton H, Gilbert PB, McElrath JM, Corey L, Self SG. Li F, et al. Among authors: gilbert pb. Curr HIV Res. 2007 Jan;5(1):97-107. doi: 10.2174/157016207779316260. Curr HIV Res. 2007. PMID: 17266561

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

323 results

Search Page

Filters